Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $122309.88 in Stock – Defense World

Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) CEO John F. Crowley sold 11,346 shares of the businesss stock in a transaction on Friday, July 1st. The stock was sold at an average price of $10.78, for a total transaction of $122,309.88. Following the completion of the sale, the chief executive officer now directly owns 910,993 shares of the companys stock, valued at $9,820,504.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

FOLD opened at $11.19 on Friday. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -11.54 and a beta of 1.07. Amicus Therapeutics, Inc. has a one year low of $5.91 and a one year high of $12.63. The business has a 50 day simple moving average of $8.48 and a two-hundred day simple moving average of $9.09. The company has a debt-to-equity ratio of 1.63, a current ratio of 4.00 and a quick ratio of 3.81.

Amicus Therapeutics (NASDAQ:FOLD Get Rating) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing analysts consensus estimates of ($0.24) by ($0.06). The business had revenue of $78.72 million during the quarter, compared to analysts expectations of $76.97 million. Amicus Therapeutics had a negative return on equity of 95.05% and a negative net margin of 84.97%. During the same period in the previous year, the business earned ($0.25) EPS. As a group, sell-side analysts expect that Amicus Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Several research analysts have recently commented on the company. StockNews.com assumed coverage on Amicus Therapeutics in a report on Thursday, March 31st. They issued a hold rating on the stock. The Goldman Sachs Group started coverage on Amicus Therapeutics in a research note on Wednesday, April 13th. They set a neutral rating for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $15.20.

About Amicus Therapeutics (Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.